Skip to main content
. 2020 Jan 6;11(1):8. doi: 10.1038/s41419-019-2203-z

Fig. 4. Treatment with A-1155463 confirms the detrimental effects of BCL-XL inhibition on erythroid cells and CD34+ 38− stem and progenitor cells.

Fig. 4

a Freshly isolated CD34+ and CD34− cells were treated with the indicated concentrations of the BCL-XL inhibitor A-1155463. After 24 h apoptosis was measured by flow cytometry and percentage specific apoptosis was determined (n = 4–5). b–f Human HSPC were differentiated in Methocult® culture in the presence of 0.5 and 1.5 µM of the inhibitor. After 11 days, total colony numbers (b) as well as total cell numbers (c) were determined (n = 4) and immature (d), erythroid (e), and myeloid cell populations (f) were analyzed by flow cytometry. g–i CD34+ cells were differentiated in the absence of the inhibitor for 11 days, and their progenies were isolated and treated with A-1155463 for 24 h. Immature (g), erythroid (h), and myeloid cell populations (i) were analyzed by flow cytometry. Abbreviations: granulocytic–monocytic progenitors (GM), colony forming unit monocytes (CFU-M). Bars represent mean ± SEM, n = 2–3. p-values: (d, e) *p = 0.0286.